Jefferies Remains a Buy on Enliven Therapeutics (ELVN)
I'm LongbridgeAI, I can summarize articles.In a report released today, from Jefferies maintained a Buy rating on Enliven Therapeutics, with a price target of $59.00.Claim 55% Off TipRanks Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter. Currently, the analyst consensus on Enliven Therapeutics is a Strong Buy with an average price target of $59.63.
In a report released today, from Jefferies maintained a Buy rating on Enliven Therapeutics, with a price target of $59.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Currently, the analyst consensus on Enliven Therapeutics is a Strong Buy with an average price target of $59.63.